Research today. Impact tomorrow.

25% Off the entire catalogue →

Same standards. Greater possibilities.

Research Use Only18+Not for Human ConsumptionReconstitution Materials Not Supplied
Peptide Database

Tissue repair & recovery research

B7-33 (Relaxin): Research Overview

Simplified relaxin analogue studied in fibrosis and cardiovascular research.

Also known as relaxin-2 analogue · B7/8-33 · Relaxin

Research use onlyStrongest evidence: animal studyReviewed
DatabaseReferences

What is B7-33?

B7-33 is a single-chain peptide analog of human relaxin-2 that selectively activates the relaxin family peptide receptor 1 (RXFP1). Unlike native relaxin-2, which requires a complex two-chain A/B structure connected by disulfide bonds, B7-33 achieves RXFP1 activation with a much simpler single-chain design. This makes it significantly easier and more cost-effective to synthesize.

What is B7-33 researched for?

  • Reduces myocardial fibrosis and collagen deposition, attenuating adverse cardiac remodeling in preclinical heart failure models.
  • Enhances nitric oxide-mediated vasodilation, reducing vascular resistance and improving blood flow in preclinical studies.
  • Demonstrates cardioprotective effects in animal models of heart failure, improving cardiac function and reducing fibrotic burden.
  • Inhibits fibroblast differentiation into myofibroblasts and reduces extracellular matrix deposition in multiple organ systems.
  • Shows protective effects against kidney fibrosis progression in preclinical disease models.

How does B7-33 work?

Selectively activates RXFP1, the primary receptor for relaxin-2, triggering downstream signaling cascades that inhibit fibroblast activation and collagen deposition, promote extracellular matrix remodeling via increased matrix metalloproteinase (MMP) activity, enhance nitric oxide-mediated vasodilation, and reduce inflammatory cytokine expression.

Reported targets: RXFP1

References

  1. A single-chain peptide derived from the relaxin B-chain selectively activates RXFP1

    Hossain, M.A., et al. · Chemical Science · 2016

    Identified B7-33 as a single-chain relaxin analog that selectively activates RXFP1, demonstrating that a simplified single-chain peptide can replicate key signaling functions of native two-chain relaxin-2.

  2. The single-chain relaxin mimetic, B7-33, maintains anti-fibrotic activity in liver and kidney fibrosis models

    Hossain, M.A., et al. · British Journal of Pharmacology · 2020

    B7-33 reduced fibrosis markers in both liver and kidney fibrosis models, demonstrating organ-protective anti-fibrotic effects comparable to native relaxin-2 despite its simplified structure.

  3. The relaxin receptor as a therapeutic target -- perspectives from evolution and drug targeting

    Bathgate, R.A.D., et al. · Pharmacology & Therapeutics · 2018

    Comprehensive review of RXFP1 as a drug target, discussing relaxin-2 and analogs including B7-33 for cardiovascular, fibrotic, and reproductive indications.

    Review or meta-analysis

  4. B7-33 replicates the vasoprotective effects of relaxin in mouse models of cardiovascular disease Marshall, S.A., et al. Annals of the New York Academy of

    Sciences · 2017

    B7-33 replicated the vasoprotective and anti-fibrotic effects of native relaxin in mouse models, reducing vascular stiffness and improving cardiovascular outcomes.

    Animal study

  5. The role of relaxin and its receptor (RXFP1) in the pathogenesis and treatment of fibrotic diseases Samuel, C.S., et al. Molecular and

    Cellular Endocrinology · 2017

    Reviews the anti-fibrotic mechanisms of relaxin/RXFP1 signaling, including inhibition of TGF-beta-driven fibroblast activation and collagen synthesis, with implications for simplified analogs like B7-33.

    Laboratory study

  6. Ensemble support vector machine classification of dementia using structural MRI and mini-mental state examination

    Sørensen L, Nielsen M, Alzheimer's Disease Neuroimaging Initiative · Journal of neuroscience methods · 2018

    PMID 29378218

  7. Santiago Ramón y Cajal's Advice for a Young Investigator

    Anderson M · Cerebrum : the Dana forum on brain science · 2016

    PMID 28058093

  8. Mechano-electric and mechano-chemo-transduction in cardiomyocytes

    Izu LT, Kohl P, Boyden PA, et al. · The Journal of physiology · 2020

    PMID 31789427

  9. Beyond nutrients: a meta-analysis of the diverse effects of arbuscular mycorrhizal fungi on plants and soils

    Delavaux CS, Smith-Ramesh LM, Kuebbing SE · Ecology · 2017

    PMID 28500779

  10. Exploring pharmacists' perceived job alternatives: Results from the 2014 National Pharmacist Workforce Survey

    Rojanasarot S, Gaither CA, Schommer JC, et al. · Journal of the American Pharmacists Association : JAPhA · 2017

    PMID 27838392

Common questions

Why is B7-33 easier to synthesize than native relaxin-2?

B7-33 is a single-chain peptide analog that retains RXFP1 activation while avoiding native relaxin-2's complex two-chain A/B structure connected by disulfide bonds. This simplified single-chain design is significantly easier and more cost-effective to synthesize while achieving equivalent biological activity.

Can B7-33 cause dangerous drops in blood pressure like other vasodilators?

Preclinical research suggests transient hypotension due to vasodilatory effects is possible. Users may experience symptomatic hypotension including dizziness or lightheadedness. Those with pre-existing hypotension or on antihypertensive medications must be cautious. No human data exists on hypotension incidence or management.